Abstract
Although imatinib is an effective treatment for chronic myelogenous leukemia (CML), and nearly all patients treated with imatinib attain some form of remission, imatinib does not completely eliminate leukemia. Moreover, if the imatinib treatment is stopped, most patients eventually relapse (Cortes et al. in Clin. Cancer Res. 11:3425–3432, 2005). In Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 2008), the authors presented a mathematical model for the dynamics of CML under imatinib treatment that incorporates the anti-leukemia immune response. We use the mathematical model in Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 2008) to study and numerically simulate strategic treatment interruptions as a potential therapeutic strategy for CML patients. We present the results of numerous simulated treatment programs in which imatinib treatment is temporarily stopped to stimulate and leverage the anti-leukemia immune response to combat CML. The simulations presented in this paper imply that treatment programs that involve strategic treatment interruptions may prevent leukemia from relapsing and may prevent remission for significantly longer than continuous imatinib treatment. Moreover, in many cases, strategic treatment interruptions may completely eliminate leukemic cells from the body. Thus, strategic treatment interruptions may be a feasible clinical approach to enhancing the effects of imatinib treatment for CML. We study the effects of both the timing and the duration of the treatment interruption on the results of the treatment. We also present a sensitivity analysis of the results to the parameters in the mathematical model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams, B. M., Banks, H. T., Kwon, H.-D., & Tran, H. T. (2004). Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng., 1(2), 223–241.
Angstreich, G., Smith, B., & Jones, R. (2004). Treatment options for chronic myelogenous leukemia: imatinib versus interferon versus allogeneic transplant. Curr. Opin. Oncol., 16, 95–99.
Bajaria, S. H., Webb, G., & Kirschner, D. E. (2004). Predicting differential responses to structured treatment interruptions during HAART. Bull. Math. Biol., 66, 1093–1118.
Chen, C., Maecker, H., & Lee, P. (2008). Development and dynamics of robust T-cell responses to CML. Blood, 111(11), 5342–5349.
Cortes, J., Talpaz, M., O’Brien, S., Jones, D., Luthra, R. et al. (2005). Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res., 11, 3425–3432.
Dingli, D., & Michor, F. (2006). Successful therapy must eradicate cancer stem cells. Stem Cells, 24, 2603–2610.
Kim, P., Lee, P., & Levy, D. (2008). Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol., 4(6), e1000095.
Komarova, N., & Wodarz, D. (2005). Drug resistance in cancer: Principles of emergence and prevention. Proc. Natl. Acad. Sci., 102, 9714–9719.
Koup, R. (2004). Reconsidering early HIV treatment and supervised treatment interruptions. PLoS Med., 1(2), e41.
Lee, S. (2000). Chronic myelogenous leukemia. Br. J. Hematol., 111, 993–1009.
Lowenberg, B. (2003). Minimal residual disease in chronic myeloid leukemia. N. Engl. J. Med., 349, 1399–1401.
Maserati, R., Foli, A., Tomasoni, L., Sighinolfi, L., Maggiolo, F., Sacchini, D., DiPietro, M., Bertelli, D., Tinelli, C., & Lori, F. (2007). Effects of structured treatment interruptions on metabolic anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART. Curr. HIV Res., 5(3), 337–343.
McKay, M. D., Conover, W. J., & Beckman, R. J. (1979). A comparison of three models for selecting values of input variables in the analysis of output from a computer code. Technometrics, 21, 239–245.
Mahon, F., Rea, D., Guilhot, F., Legros, L., Guilhot, J., Aton, E., Dulucq, S., Reiffers, J., & Rousselot, P. (2009). Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial. J. Clin. Oncol., 27, 7084.
Michor, F., Hughes, T., Iwasa, Y., Branford, S., Shah, N., Sawyers, C., & Nowak, M. (2005). Dynamics of chronic myeloid leukemia. Nature, 435, 1267–1270.
Piazza, R., Magistroni, V., Franceschino, A., Andreoni, F., Tornaghi, L. et al. (2006). The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol. Dis. 37, 111–115.
Roeder, I., & Glauche, I. (2008). Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia–insights from mathematical model analyses. J. Mol. Med., 86, 17–27.
Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M. et al. (2006). Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical applications. Nat. Med., 12, 1181–1184.
Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M. et al. (2007). Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109, 58–60.
Sawyers, C. (2000). Chronic myeloid leukemia. N. Engl. J. Med., 340, 1330–1340.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paquin, D., Kim, P.S., Lee, P.P. et al. Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia. Bull Math Biol 73, 1082–1100 (2011). https://doi.org/10.1007/s11538-010-9553-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-010-9553-0